Cancer Control最新文献

{"title":"Gender Differences in Prognosis of Pancreatic Neuroendocrine Tumors: A Retrospective Cohort Study Based on the SEER Database.","authors":"Yining Li, Shuaiyang Zhou, Qiao Qiao, Ke Ji, Qin Li, Zhenguo Qiao, Ping Zhang","doi":"10.1177/10732748261417419","DOIUrl":"10.1177/10732748261417419","url":null,"abstract":"<p><p>IntroductionWhile gender is a known prognostic factor for many cancers, its specific role in pancreatic neuroendocrine tumors (PanNETs) survival remains poorly characterized. This study aimed to investigate gender-based differences in PanNETs prognosis using the Surveillance, Epidemiology, and End Results (SEER) database.MethodsThis retrospective cohort study included patients diagnosed with PanNETs between the years 2000 and 2020, extracted from the SEER database. Propensity score matching (PSM) was applied to mitigate potential selection bias. Overall survival (OS) was evaluated using Kaplan-Meier analysis and multivariable Cox regression.ResultsAmong the 5155 patients included (2814 males, 2341 females), males showed significantly worse OS than females both before (hazard ratio [HR] 1.29, 95% CI 1.14-1.47, <i>P</i> < 0.001) and after (HR 1.19, 95% CI 1.02-1.38, <i>P</i> = 0.026) PSM. Subgroup analyses confirmed a consistent OS advantage for females across most categories. Multivariable analysis identified marital status, age, tumor grade, gender, year of diagnosis, N stage, M stage, and surgical intervention as independent predictors of OS. Similar predictors were found in males, whereas in females, marital status, age, grade, N stage, M stage, and surgery were specifically significant.ConclusionsFemale patients with PanNETs exhibit superior OS rates. Further research is needed to clarify the biological and clinical mechanisms underlying these gender-related disparities.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261417419"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Performance of Visual Inspection with Acetic Acid and Colposcopy for Detection of Cervical Precancer in Women with High-Risk Human Papillomavirus Infection: A Cross-Sectional Study.","authors":"Sompop Kuljarusnont, Wathirada Karnchanabanyong, Irene Ruengkhachorn, Methawee Ularnwong, Pornprom Ittiamornlert, Suchanan Hanamornroongruang","doi":"10.1177/10732748261422014","DOIUrl":"10.1177/10732748261422014","url":null,"abstract":"<p><p>IntroductionThe World Health Organization recommends 4 triage strategies for women with high-risk human papillomavirus infection (hrHPV). These include visual inspection with acetic acid (VIA), colposcopy, reflex cytology, and HPV16/18 partial genotyping. However, in many low-resource settings, access to colposcopy remains limited. This study aimed to compare the diagnostic accuracy of visual inspection vs colposcopy for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2⁺).MethodsWomen who tested positive for hrHPV and were referred for colposcopy, with cytology results available as part of routine clinical care, underwent visual inspection with 3% acetic acid immediately before colposcopy. Colposcopic impressions were recorded, and images were scored using a modified Reid colposcopic index and a modified Swede score without iodine staining. We compared diagnostic performance for CIN2⁺ across visual inspection, colposcopic impression, modified Reid index (score ≥4), and modified Swede score (score ≥5). Statistical analysis used IBM SPSS Statistics and the Cochran Q test, with significance set at <i>P</i> < .05.ResultsAmong 450 women, the median age was 38.0 years. A single hrHPV type was detected in 70.4% of cases; types 16, 52, and 18 were most common. Histopathological confirmation of CIN2⁺ occurred in 97 women (21.6%). Diagnostic accuracy for predicting CIN2⁺ was 78.2% with VIA and 77.5% with colposcopic impression. Accuracy was 78.4% for the modified Reid index ≥4 and 78.2% for the modified Swede score ≥5. No significant differences were observed among the 4 methods (<i>P</i> = .941).ConclusionsVIA demonstrates diagnostic accuracy comparable to colposcopy-based assessments in hrHPV-positive women evaluated within a cytology-informed clinical pathway, supporting its potential role in resource-limited settings.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261422014"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12852574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study.","authors":"Nilanchali Singh, Shalini Singh, Rizwana Quraishi, D N Sharma, Zakiya Zakiya, Seema Singhal, Jyoti Meena, Shivangi Mangal, Garg Himakshi, Rajesh Kumari, Anju Singh, Neena Malhotra","doi":"10.1177/10732748261465284","DOIUrl":"10.1177/10732748261465284","url":null,"abstract":"<p><p>IntroductionFemale sexual dysfunction (FSD) in any gynaecological cancer survivor is one aspect of female functioning that is neglected in survivorship care. Therefore, their actual prevalence is far from known to the treating physician. This study aimed to evaluate the prevalence of sexual dysfunction in gynaecological cancer survivors, determine its risk factors, and correlate sexual dysfunction with serum neurotropic factors.MethodsThis was a cross-sectional, observational study among 200 gynaecological cancer survivors who are sexually active, conducted in the gynaecological cancer clinic at a tertiary care centre. Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), and serum brain-derived neurotrophic factor (BDNF), substance P, and neuropeptide Y (NPY) were measured by ELISA. The correlation between these biomarkers, with domains and subdomains of the female sexual function index, was explored.ResultsIn this cohort of 200 gynaecological cancer survivors, 189 (94.5%) women had FSD (FSFI <26.55). Age was the only independent clinical predictor of FSD in multivariable analysis (p = 0.02), while cancer site, stage, treatment modality, and menopausal status were not significant in this cohort. Overall biomarker levels did not differ between women with and without FSD. However, subdomain analysis showed high dysfunction rates in lubrication, orgasm, pain, and arousal, with significant biomarker differences for substance P and NPY in several dysfunctional subdomains.ConclusionsFSD was highly prevalent in gynaecological cancer survivors. While overall biomarker differences were not significant, subdomain-specific associations suggest that substance P and NPY may have a role in domain-level sexual dysfunction and merit further study.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261465284"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Impact of Patient Selection and Analytical Methods on mRNA Biomarker Identification in Ovarian Cancer Using TCGA Data.","authors":"Sara Cocchi, Melanija Talijanovic, Estrid V Høgdall, Joanna Lopacinska-Jørgensen","doi":"10.1177/10732748261468094","DOIUrl":"10.1177/10732748261468094","url":null,"abstract":"<p><p>IntroductionThe Cancer Genome Atlas (TCGA) data has been extensively used for differentially expressed genes (DEGs) discovery and validation in high-grade serous ovarian cancer (HGSOC), however platinum-sensitivity biomarkers have not yet reached clinical application. We aimed to propose a robust analytical framework for TCGA platinum sensitivity studies and systematically demonstrate how patient characteristics influence DEG analyses between platinum-sensitive and resistant groups, while also considering experimental platforms and analysis pipelines, as their impact is recognized but not comprehensively evaluated.MethodsThis retrospective TCGA cohort study used publicly available microarray and RNA-seq gene expression data. TCGA-derived datasets were identified through a literature review, including only studies enabling unambiguous patient identification. Three TCGA-based cohorts were assembled-two directly from published studies and one curated through own selection-differing in patient numbers (230, 201 and 142 patients, respectively) and stage distribution. Data were analyzed using <i>DESeq2</i>, <i>edgeR</i>, <i>limma-voom</i>, and Wilcoxon rank-sum test to compare the impact of patient selection and pipeline choice on DEGs outcome. Genes with an adjusted p-value < 0.05 and an |log₂ fold change| > 2 were considered differentially expressed.ResultsThe three cohorts showed partial overlap of DEGs across platforms and pipelines. Both patient selection and analytical workflow influenced which genes were identified, highlighting findings variability even when using the same TCGA dataset. We establish a robust analytical framework for TCGA HGSOC biomarker studies, including the provision of patient barcodes and openly shared workflows that enable straightforward replication of our analyses from data download to DEG analysis.ConclusionsReproducibility of TCGA studies is limited by variability in patient selection, platinum sensitivity definitions, data sources, and analysis pipelines. We addressed these factors by providing a robust framework that can serve as a template for data analysis and transparent reporting when identifying and validating predictive signatures of platinum sensitivity in HGSOC patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261468094"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148680787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Human Papillomavirus Type 16 E6 Seroprevalence and Degrees of Anal Disease Among Men With HIV: A Nested Case Control Study.","authors":"Krystle A Lang Kuhs, Christopher Otieno, Staci Sudenga, Tim Waterboer, Weiqun Tong, Dorothy Wiley, Jay H Bream, Steven Wolinsky, Jeremy Martinson, Gypsyamber D'Souza","doi":"10.1177/10732748261462289","DOIUrl":"10.1177/10732748261462289","url":null,"abstract":"<p><p>IntroductionHuman papillomavirus type 16 (HPV16) E6 antibodies may be an early biomarker of anal cancer. We cross-sectionally evaluated when in the course of anal disease, HPV16 antibodies are induced.MethodsA nested case-control study of 846 men who have sex with men (MSM) was conducted within a prospective study of men with and without HIV. Cases of anal HPV16 (N=262), biopsy-confirmed high-grade squamous intraepithelial lesion (HSIL;N=140), and anal cancer (N=21) were individually matched to controls (N=423) on HIV status, study-participation duration, and age. Serum samples closest to diagnosis underwent HPV serologic testing; prediagnostic serial samples were tested for anal cancers only. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs).ResultsHPV16 E6 seroprevalence was non-significantly elevated in anal disease: OR:1.6 (95%CI:0.7-3.6) for HPV16 infection; OR:1.4 (95%CI:0.5-3.8) for HSIL; and OR:1.5 (95%CI:0.3-9.0) for anal cancer. HPV16 E6 seroprevalence was dramatically lower among men with versus without HIV with the same disease stage: 1.5% vs. 11.2% (<i>P</i><0.001) for anal HPV16 infection; 4.2% vs. 13.6% (<i>P</i>=0.043) for HSIL; and 5.6% vs. 66.7% (<i>P</i>=0.005) for anal cancer. HPV16 E6 seroprevalence was only associated with anal HPV16 among men without HIV (OR:2.9 [95%CI:1.0-8.0]); no significant associations between HPV16 E6 seroprevalence and anal disease were observed among men with HIV. Among the 21 anal cancers, 66.7% (2/3) without HIV and 5.6% (1/18) with HIV were HPV16 E6 seropositive before diagnosis.ConclusionsHPV16 E6 antibodies show poor sensitivity for anal cancer and its precursors, particularly among men with HIV.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261462289"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer.","authors":"Shihao Ning, Huiming Wu, Renkai Guo, Min Deng, Yipeng Cui, Dingwen Xue, Chunchen Li, Chenfei Jin, Huiyu Li","doi":"10.1177/10732748261430581","DOIUrl":"10.1177/10732748261430581","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related mortality worldwide. Currently, surgical resection remains the cornerstone of curative treatment for CRC; however, patients with advanced disease continue to face significant risks of postoperative recurrence and metastasis. Although immune checkpoint inhibitors (ICIs), represented by PD-1/PD-L1 monoclonal antibodies, have reshaped the therapeutic landscape of various solid tumors, their clinical benefit in CRC is strictly limited by mismatch repair (MMR) status, leaving the vast majority of proficient mismatch repair/microsatellite stable (pMMR/MSS) patients with minimal therapeutic gain. Importantly, tumor-associated macrophages (TAMs)-a key regulatory component of the tumor immune microenvironment-not only exert immunosuppressive functions through PD-1 and multiple other pathways, but also promote PD-1 expression on tumor cells via distinct mechanisms. Consequently, accumulating evidence suggests that TAMs play a critical role in mediating resistance to PD-1/PD-L1 inhibitors in CRC. Nevertheless, research on the underlying mechanisms remains at an early stage. This narrative review aims to summarize the latest advances regarding the involvement of TAMs in resistance to PD-1/PD-L1 blockade, with a particular focus on strategies to enhance immunotherapy responsiveness through TAM modulation. We further discuss limitations in current clinical studies and propose potential directions for future research. By juxtaposing successful mechanistic studies with underwhelming clinical trial data, we aim to redefine the therapeutic rationale for combining TAM-targeted agents with immune checkpoint blockade.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261430581"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12954014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on Unresolved Methodological Issues.","authors":"Bill Byrom, John Devin Peipert","doi":"10.1177/10732748261432279","DOIUrl":"10.1177/10732748261432279","url":null,"abstract":"<p><p>Patient-reported outcomes assessing treatment toxicity and its impact, and aspects of quality of life, have become increasingly important components of oncology drug development including early phase dose optimization studies. Despite insights from these data, there are limitations on drawing inferences about whether a treatment is tolerable or intolerable, which requires understanding individual risk-benefit assessments that vary between patients, cancer types, and stages of disease. This commentary examines unresolved methodological issues requiring more research rigor and attention: the development of tolerability thresholds based upon toxicity severity data; the direct measurement of tolerability through specific patient self-report measures; and overcoming the challenge of baseline value assessment in important measures such as single item side-effect bother assessments. We call for further research to resolve these challenges and drive more robust inference-making from patient-reported outcomes data collected in cancer clinical trials.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261432279"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12961095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed-Method Formative Evaluation and Cultural Adaptation of Digital Health Communication Content and Delivery Promoting Lung Cancer Screening Shared Decision-Making.","authors":"Andy J King, Indy Li, Jennyffer P Morales, Anthony Banks, Ellen Wight, Kimberly A Kaphingst, Cho Y Lam, Peter A Taber, Emerson P Borsato, Chelsey R Schlechter, Guilherme Del Fiol, Kensaku Kawamoto, David W Wetter","doi":"10.1177/10732748261456371","DOIUrl":"10.1177/10732748261456371","url":null,"abstract":"<p><p>IntroductionLung cancer remains a leading cause of cancer death, though lung cancer screening (LCS) uptake remains low, particularly among low-resource patient populations. LungSMART Utah uses a multi-level approach to promote LCS to patients served by Community Health Centers (CHCs). This paper reports on the formative evaluation and cultural adaptation of the project's patient-facing digital health communication content and delivery, in service of the larger population health effort to promote shared decision-making for LCS.MethodsWe used a mixed-method approach (cross-sectional surveys and usability observations) to evaluate developed content and ensure cultural adaptation to serve all patients within the CHCs. First, a messaging study (<i>N</i>=79) used an online survey to evaluate patient perceptions of content quality and to collect feedback on the quality of content in both English and Spanish. Second, a usability assessment (<i>N</i>=17) employed think-aloud protocols to evaluate user experience and technical delivery.ResultsPatients in the messaging study generally rated content favorably. Content evaluations were similar in English and Spanish, though some participants did suggest phrasing changes. The usability assessment identified critical technical and delivery hurdles, including feeling overloaded by choices for some project components and message sequencing concerns. Cultural adaptation insights from Spanish-speaking participants highlighted the need for conversational alternatives to some formal medical terms, explicit transparency about cost, and addressing access anxiety. All participants indicated noting message content came from the CHCs helped foster trust.ConclusionMixed-method formative evaluation and cultural adaptation provide important insights for developing digital population health tools. Addressing technical delivery gaps and specific community concerns will improve the reach and efficacy of LCS promotion in low-resource settings.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261456371"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148036994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geographic and Demographic Disparities in Receipt of Treatment for Early-Onset Colorectal Cancer.","authors":"Meng-Han Tsai, Steven S Coughlin, Jorge Cortes","doi":"10.1177/10732748261433621","DOIUrl":"10.1177/10732748261433621","url":null,"abstract":"<p><p>PurposeTo examine disparities in receipt of the first course of treatment modality used among individuals diagnosed with early-onset colorectal cancer, focusing on sex, race/ethnicity, and rurality differences.MethodsWe conducted a cross-sectional analysis utilizing national data from the 2006-2020 Surveillance, Epidemiology, and End Results Program among adults aged 20-49. Key factors included sex, race/ethnicity, and rurality. Our main outcomes were whether patients started treatment, and which types they received. Multivariable logistic regression models were performed.ResultsOf total 82,427 patients, males (54.9%, p=0.097), racial minorities (0.8%-23.3%, p<0.001), and patients in all urban areas (70.7%; p<0.001) had higher rates of no treatment. Adjusted analysis showed that male patients had16%-19% lower odds of receiving surgery regardless of rurality (p<0.05) compared with female patients. In all/mostly urban areas, Black patients were found to had 17%-41% lower odds of receiving any treatment modalities (p<0.05); Hispanic patients had 11%-24% lower odds of receiving any treatment modalities (mostly urban: OR, 0.76; 95% CI, 0.60-0.95) or surgery alone (all urban: OR, 0.89; 95% CI, 0.84-0.95) compared with White patients. In rural areas, 33% and 34% lower odds of receiving radiation treatment were found among American Indian (AI)/Alaska Native (AN) (OR, 0.67; 95% CI, 0.46-0.98) and Asian/Pacific Islander (PI) patients (OR, 0.66; 95% CI, 0.44-0.99) compared with White patients, respectively.ConclusionsDisparities in receipt of surgery treatment were observed in males regardless of rurality. Black and Hispanic patients in urban areas had lower treatment use, while AI/AN and Asian/PI patients in rural areas were less likely to start radiation. Targeted approaches for specific groups are needed.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261433621"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147693086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer.","authors":"Xin Ma, Jing Du, Donghai Li","doi":"10.1177/10732748261481227","DOIUrl":"10.1177/10732748261481227","url":null,"abstract":"<p><p>This narrative review systematically examines the potential of circular RNAs (circRNAs) as clinical biomarkers in breast cancer, focusing on the translational gap between basic discoveries and clinical applications. circRNAs are covalently closed non-coding RNA molecules characterized by high stability and tissue-specific expression, making them promising candidates for liquid biopsy. In breast cancer, a highly heterogeneous disease, circRNA expression profiles exhibit subtype-specific patterns and are associated with tumorigenesis, progression, and therapeutic resistance. Mechanistically, circRNAs function as microRNA sponges, interact with RNA-binding proteins, and can even encode functional polypeptides, thereby influencing cancer stem cell properties, immune escape, and organ-specific metastasis. Tumor-derived extracellular vesicles (EVs) carry circRNA signatures that offer a novel source for non-invasive biomarker detection. However, clinical translation is hindered by challenges in detection standardization, functional validation, and a lack of prospective, large-cohort studies. This review critically evaluates the biological functions and clinical relevance of circRNAs, discusses the role of EV-derived circRNAs in metastasis monitoring, and outlines a roadmap to overcome current translational bottlenecks, ultimately assessing their potential as diagnostic, prognostic, and predictive tools in breast cancer management.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261481227"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148800335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}